Search
for
Sort by
Research 61–90 of 80
- Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Impact of Medical Castration on Malignant Arrhythmias in Patients With Prostate Cancer
- Androgens in cervical cancer: Their role in epidemiology and biology
- Development of a Carvedilol-Loaded Solid Self-Nanoemulsifying System with Increased Solubility and Bioavailability Using Mesoporous Silica Nanoparticles
- Antiandrogens as Therapies for COVID-19: A Systematic Review
- The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
- Cancer-Related Alopecia: From Etiologies to Global Management
- A Review of the Characteristics of Clinical Trials and Potential Medications for Alcohol Dependence: Data Analysis from ClinicalTrials.gov
- Selective Sensing of Darolutamide and Thalidomide in Pharmaceutical Preparations and in Spiked Biofluids
- SRD5A2 and emerging therapies in androgen-driven disorders
- Low-Dose Dimethyl Sulfoxide (DMSO) Suppresses Androgen Receptor (AR) and Its Splice Variant AR-V7 in Castration-Resistant Prostate Cancer (CRPC) Cells
- Does Androgenic Alopecia Aggravate the Risk of Prostate Cancer? Evidence from Mendelian Randomization
- Identification of Potential Cytochrome p450c 17 Alpha Inhibitors for the Treatment of PCOS via Scaffold Hopping and Fragment-Based De-Novo Drug Design
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Alternative androgen pathways
- Triple Hormonal Blockade (ADT3): A Patient’s Perspective
- Prostatakarzinom
- Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
- Abiraterone and spironolactone in prostate cancer: a combination to avoid
- Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- Revising the role of the androgen receptor in breast cancer
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Are sex discordant outcomes in COVID-19 related to sex hormones?
- Redefining hormone resistance in prostate cancer
- HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
- Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation
- Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 <i>in vitro</i> infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
- Editorial: Androgen-dependent diseases and their treatment